
==== Front
J Clin Invest
J Clin Invest
J Clin Invest
The Journal of Clinical Investigation
0021-9738
1558-8238
American Society for Clinical Investigation

39286985
176507
10.1172/JCI176507
Clinical Medicine
Prebiotics improve frailty status in community-dwelling older individuals in a double-blind, randomized, controlled trial
Yang Jie jieer1226@163.com
1
Hou Liming houlm11@163.com
1
Wang Anhui wangah@fmmu.edu.cn
2
Shang Lei shanglei@fmmu.edu.cn
3
Jia Xin jiaxin_09@hotmail.com
1
Xu Rong xurongkeke@126.com
1
Wang Xiaoming xmwang@fmmu.edu.cn
1
1 Department of Geriatrics, Xijing Hospital,
2 Department of Epidemiology, and
3 Department of Health Statistics, Air Force Medical University, Xi’an, China.
Address correspondence to: Xiaoming Wang, Department of Geriatrics, Xijing Hospital, Air Force Medical University, 127 Changle West Road, Xi’an 710032, China. Phone: 86.29.84775543; Email: xmwang@fmmu.edu.cn.
Authorship note: JY and LH contributed equally to this work and are co–first authors.

6 8 2024
17 9 2024
6 8 2024
134 18 e17650713 10 2023
29 7 2024
© 2024 Yang et al.
2024
Yang et al.
https://creativecommons.org/licenses/by/4.0/ This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
This article is available online at https://www.jci.org/articles/view/176507
BACKGROUND

Frailty significantly affects morbidity and mortality rates in the older population (age >65 years). Age-related degenerative diseases are influenced by the intestinal microbiota. However, limited research exists on alterations in the intestinal microbiota in frail older individuals, and the effectiveness of prebiotic intervention for treating frailty remains uncertain.

OBJECTIVE

We sought to examine the biological characteristics of the intestinal microbiome in frail older individuals and assess changes in both frailty status and gut microbiota following intervention with a prebiotic blend consisting of inulin and oligofructose.

METHODS

The study consisted of 3 components: an observational analysis with a sample size of 1,693, a cross-sectional analysis (n = 300), and a multicenter double-blind, randomized, placebo-controlled trial (n = 200). Body composition, commonly used scales, biochemical markers, intestinal microbiota, and metabolites were examined in 3 groups of older individuals (nonfrail, prefrail, and frail). Subsequently, changes in these indicators were reevaluated after a 3-month intervention using the prebiotic mixture for the prefrail and frail groups.

RESULTS

The intervention utilizing a combination of prebiotics significantly improved frailty and renal function among the older population, leading to notable increases in protein levels, body fat percentage, walking speed, and grip strength. Additionally, it stimulated an elevation in gut probiotic count and induced alterations in microbial metabolite expression levels as well as corresponding metabolic pathways.

CONCLUSIONS

The findings suggest a potential link between changes in the gut microbiota and frailty in older adults. Prebiotics have the potential to modify the gut microbiota and metabolome, resulting in improved frailty status and prevention of its occurrence.

TRIAL REGISTRATION

ClinicalTrials.gov NCT03995342.

The intestinal microbiota may be associated with frailty in elderly individuals and that prebiotics could modulate the intestinal microbiota and metabolome.

Aging
Clinical trials
Clinical practice
National Key R&D Program of ChinaProject2020YFC2008000
==== Body
pmcIntroduction

Approximately 21.3% of the global population will be 60 years of age or older by 2050, with the global life expectancy at birth increasing from 66.8 years in 2000 to 73.3 years in 2019. However, a healthy, disease-free lifespan (health span) has not increased as much as lifespan, as advanced age is a major risk factor for several diseases, including cancer, cardiovascular disease, and neurodegenerative disease, and the increasing proportion of unhealthy older people is posing a global challenge to society (1, 2). Frailty, characterized by exhaustion, chronic malnutrition, decreased physical activity, and mobility disorders affects more than 13.6% of older adults globally (3, 4) This syndrome represents the most challenging aspect of population aging, as it substantially increases the risk of falls, disability, long-term care, and even death among older people. In addition to heightened vulnerability and individual dependence, the proposed mechanisms underlying frailty include chronic inflammation, immune system disorders, and mitochondrial DNA abnormalities (5, 6). At present, effective prevention and treatment measures for frailty are lacking, and the common intervention measures, including exercise, nutritional supplementation, rational drug treatment, comorbidity management, and psychological intervention, are still being explored (5, 7).

The intestinal microbiota of the fetus begins to build up in the womb and undergo rapid modification during the first 3 years of life, followed by relative stabilization until 65 years of age. Then, the composition of the microbiota begins to change gradually and accelerates after 70 years of age, with increased variability, reduced biodiversity, and pathogen colonization (8, 9). Microorganisms are dynamic, adaptable, and plastic, and their composition shows great individual differences; therefore, they are also known as “the second genome,” which affects health status. Growing evidence indicates a relationship between the intestinal microbiota and a broad range of diseases, including obesity, type 2 diabetes, and chronic and geriatric syndromes (10, 11). Previous research conducted in frail older adults has suggested that altered intestinal permeability and changes in the intestinal muscle axis and the gut-brain axis may be key factors associated with the pathophysiology of frailty (12, 13). In contrast, however, 2 studies involving community-dwelling adults showed that frailty was negatively associated with intestinal microbiota diversity (14, 15).

In the past decade, understanding of the intestinal microbiota has rapidly increased, accompanied by increased interest in prebiotics as a means to modulate the intestinal microbiota, as they have been defined as nondigestible food ingredients that confer multiple health benefits by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon when administered in adequate amounts (16, 17). Paul et al. pointed out in 2015 that, because the microbiota may modulate aging-related changes in innate immunity, sarcopenia, and cognitive function, all of which are elements of frailty, the potential for the intestinal microbiota to affect health has a particular relevance for older individuals (18). In recent years, 5 review articles have discussed the link between physical frailty and intestinal microbiota (19–23) and concluded that, given the lack of targeted studies and the influence of a large number of covariates, including diet, exercise, multimorbidity, and polypharmacy on both microbiota composition and physical function in older individuals, the causal link between microbiota and frailty is still uncertain. Moreover, 2 clinical studies have investigated the effects of prebiotics on frail older people. Cristina et al. reported an improvement in several frailty parameters (exhaustion and handgrip strength) through the use of prebiotics, but these studies focused only on observing frailty status and lacked information on whether the changes in frailty status are related to the gut microbiota and its metabolites (24, 25). Several reviews of the current scientific literature have shown that the use of prebiotics is a cost-effective and widely available intervention that may improve the homeostasis of the intestinal microbiota and prevent frailty and unhealthy aging, but no direct conclusions can be drawn regarding the efficacy of these measures (26–29). In addition, all of the previous studies have overlooked the large number of older people in the prefrail stage, considering that these individuals constitute a significant proportion of the community (as confirmed in 2021 by Nicola Veronese, who estimated that the prevalence of prefrailty was 36.4%; ref. 30).

In summary, the relationship between the intestinal microbiota and frailty status remains a very promising area of research for the future. Therefore, in this study, for the first time, we aimed not only to observe differences in the intestinal microbiota and metabolome between frail and prefrail older individuals but also to explore the effects of a 12-week prebiotic intervention on older people with different frailty states and to determine whether prebiotic supplementation could modulate the intestinal microbiota and metabolome and improve frailty status in this population.

Results

Frailty status screening in the older population

A total of 1,693 older individuals (>65 years of age) were screened for frailty status (Table 1): 703 were in the nonfrail group (N), 705 were in the prefrail group (P), and 285 were in the frail group (F). The overall prevalence of prefrailty was 41.6% (53.4% for men and 33.0% for women, P < 0.001), and the prevalence of frailty was 16.8% (16.7% for men and 16.9% for women, P = 0.892). The mean ages of the 3 groups were significantly different (P < 0.001), and the degree of frailty was positively correlated with age. With increasing frailty severity, the number of older people who experienced weight loss and physical decline increased, accompanied by slower walking speed, decreased grip strength, and increased exhaustion score, and there were significant differences between the groups (P < 0.01).

Differences between groups with different frailty states among older people

Sociodemography and general health status.

The results showed that there were statistically significant differences (P < 0.05) among the 3 groups (n = 300 total) of older people in terms of age, number of children, number of comorbidities, surgical history, exercise frequency, degree of exhaustion, and whether acute events occurred in the past year. A high frequency of exercise was a protective factor and negatively correlated with frailty. There were no statistically significant differences (P > 0.05) with regard to sex, BMI, occupation, education level, marital status, income status, living situation, tobacco consumption, or alcohol consumption (Table 2).

Differences in frailty indicators, scale scores, body composition, and food and main nutrient intake among groups with different frailty states.

Compared with the individuals in group F, the scores for daily living ability (ADL) in groups N and P were higher, indicating that the self-care ability of frail older individuals was poorer (P = 0.019 and P = 0.049). The sleep quality score (PSQI) for group F was higher than that of group N, indicating that the sleep quality of frail older individuals was poor (P < 0.001). There was no significant difference between the other scales (P > 0.05). There were no significant differences in body weight, BMI, body fat percentage, muscle mass, estimated bone mass, basal metabolism, or body moisture rate among the 3 groups (P > 0.05), except for significant differences in visceral fat (P = 0.009). Visceral fat in group F was significantly lower than that in group N (P = 0.004). There was no difference among the other groups (N vs. P, Z = 5.0, P = 0.025; P vs. F, Z = 0.794, P = 0.373) (Table 3). The intake of dairy products in the frail group was greater than that in the nonfrail group (Z = 9.043, P = 0.003), and there was no statistically significant difference among the other groups (N vs. P, Z = 2.114, P = 0.146; P vs. F, Z = 2.919, P = 0.088). There were no significant differences in other food categories or main nutrients (P > 0.05) (Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/JCI176507DS1).

Differences in liver and kidney function and cytokine levels among groups with different frailty states.

Among the 16 biochemical indicators, 10 were significantly different: albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, cystatin C, direct bilirubin, globulin, indirect bilirubin, total bilirubin, and total protein. There were no significant differences in the levels of albumin/globulin, alkaline phosphatase, AST/ALT, urea, uric acid, or γ-glutamyltransferase among the 3 groups (P > 0.05). The level of albumin in the frail group was significantly lower than that in the nonfrail group (P = 0.003) or the prefrail group (P = 0.001). There were significant differences in creatinine among the 3 groups: compared with the nonfrail group, the prefrail group had an increase in creatinine (P = 0.027), whereas the frail group had a decrease in creatinine (P = 0.049), and the creatinine level of the frail group was significantly lower than that of the prefrail group (P < 0.001). For cystatin C, both the nonfrail group and the frail group had significantly lower cystatin C levels than did the prefrail group (P < 0.001). The serum globulin level was significantly lower in the frail group than in the nonfrail group (P = 0.006). However, total protein was significantly lower in the frail group than in the nonfrail and prefrail groups (P = 0.003 and P = 0.017, respectively). Direct bilirubin levels were significantly higher in the prefrail and frail groups than in the nonfrail group (P < 0.001 and P = 0.034, respectively). However, indirect bilirubin levels were significantly lower in the prefrail and frail groups than in the nonfrail group (P = 0.014 and P < 0.001, respectively). Total bilirubin levels were significantly lower in the frail group than in the nonfrail and prefrail groups (P < 0.001 and P = 0.011, respectively). ALT levels were significantly lower in the frail group than in the nonfrail and prefrail groups (P = 0.002 and P = 0.001, respectively). AST levels were also significantly lower in the frail group than in the nonfrail and prefrail groups (P < 0.001 and P = 0.002, respectively). In conclusion, from the nonfrail group to the frail group, albumin, globulin, total protein, ALT, AST, indirect bilirubin, and total bilirubin levels all gradually decreased with the progression of disease. However, creatinine, cystatin C, and direct bilirubin levels initially increased and then decreased.

In addition, there were significant differences in the levels of the 3 cytokines among the groups (P < 0.05). Compared with the nonfrail group, the prefrail group had significantly lower levels of IFN-γ (P = 0.005). The levels of IL-17 (P = 0.005), IFN-γ (P < 0.001), and insulin-like growth factor 1 (IGF-1) (P < 0.001) were significantly increased in the frail group. Compared with the prefrail group, IFN-γ levels in the frail group were significantly increased (P < 0.001) and IGF-1 levels were significantly decreased (P < 0.001). It is worth noting that in the process of disease progression from the nonfrail stage to the frail stage, IL-17 showed a gradual increase, whereas IFN-γ showed a trend of first decreasing and then increasing, and IGF-1 showed a trend of first increasing and then decreasing, which is worthy of further exploration (Table 4).

Intestinal microbiota and metabolic characteristics in older individuals with different frailty states

Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria were the main bacteria found among the older individuals (n = 300) (Table 5). As the degree of frailty changed, the species and abundance of the gut microbiota also changed. The relative abundance of Bacteroides vulgatus, Ruminococcus bicirculans, Alistipes onderdonkii, Bacteroides ovatus, Bacteroides fragilis, Bacteroides caccae, Bacteroides thetaiotaomicron, and Bacteroides plebeius increased substantially, while that of Ruminococcus bromii, Lactobacillus ruminis, Anaerostipes hadrus, Eubacterium hallii, and Bifidobacterium adolescentis, among others, decreased (Supplemental Figure 2).

The results of untargeted metabolomics detection of intestinal microbiota metabolites revealed a total of 664 metabolites, including 435 positive ion metabolites and 229 negative ion metabolites. There were 143 different metabolites between groups N and P, 50 between groups N and F, and 192 between groups P and F. The metabolite comparisons between groups are shown in Supplemental Figure 3 from both positive and anionic perspectives.

Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed that, compared with group N, metabolic pathways, including protein digestion and absorption, amino acid biosynthesis, ABC transport, mineral absorption, and alanine, tyrosine, and tryptophan biosynthesis were upregulated in group P (P < 0.05). Pyrimidine metabolism, pentose glucuronic acid conversion, and unsaturated fatty acid synthesis pathways were downregulated in group F (P < 0.05). Compared with group P, protein digestion and absorption, amino acid biosynthesis, ABC transport, and other differential metabolic pathways were downregulated in group F (P < 0.05) (Supplemental Figure 4).

Comparison of baseline data between groups with different frailty states before intervention

There were no significant differences (P > 0.05) in age, sex, indicators of frailty, scales, or body composition between the placebo group and the probiotic mixture group in the prefrail group (n = 200) at baseline (Supplemental Table 2). Only oil intake was significantly different (P = 0.004), whereas the intake of other dietary components and major nutrients showed no statistical differences (P > 0.05) (Supplemental Table 3). There were statistically significant differences in the biochemical indices and cytokine levels of ALT, globulin, γ-glutamyltransferase, and IFN-γ (P < 0.05), but there were no significant differences in the other parameters (Supplemental Table 4).

No statistically significant differences (P > 0.05) were noted in terms of age, sex, the 5 indicators of frailty, scales, body composition tests, or the intake of major dietary and nutritional elements between the placebo group and the probiotic mixture group in the frail group at baseline (Supplemental Tables 5 and 6). Only cystatin C showed a significant difference (P = 0.006) in liver and kidney function and cytokine levels, whereas no significant difference was found in the other parameters (P > 0.05) (Supplemental Table 7).

Prebiotic intervention in older individuals with different frailty states (randomized, controlled trial)

After 12 weeks of intervention, the prebiotic mixture significantly improved frailty status in both the frail and prefrail groups, reduced exhaustion in the prefrail group, and improved walking speed in the frail group (P < 0.05). The body fat percentage significantly increased in the treatment arm, whereas muscle mass decreased in the placebo control arm among prefrail older individuals. Walking speed and grip strength improved in the treatment arm, while body fat increased and moisture percentage decreased in the placebo control arm among frail older people (P < 0.05) (Table 6). Urea and creatinine decreased, whereas globulin and total protein increased substantially in the treatment arm; γ-glutamyltransferase and indirect bilirubin increased in the placebo control arm among prefrail older individuals. Globulin levels increased, whereas IL-17 and IFN-γ levels showed a more obvious downward trend, although no statistically significant difference was found in the treatment arm; AST increased and cystatin C decreased in the placebo control arm among frail older individuals (Table 7). In summary, a prebiotic mixture can markedly increase protein levels in older individuals (both frail and prefrail), improve renal function (prefrail), and partially reduce inflammatory factors (frail).

The Table 8 lists the microbiota and metabolism after the interventions. There was no significant change in α-diversity among the groups after the intervention (P > 0.05). The results of the Tukey test showed that there was significant β-diversity between the subgroup in the prefrailty group that received maltodextrin placebo (PM group) after placebo intervention (PMA) and the subgroup in the prefrailty group that received prebiotic intervention (a prebiotic mixture of inulin and oligofructose) (PI group) after prebiotic intervention (PIA), as well as between the subgroup in the frailty group that received maltodextrin placebo intervention (FM group) after placebo intervention (FMA) and the frailty group that received prebiotic intervention (a prebiotic mixture of inulin and oligofructose) (FI group) after prebiotic intervention (FIA), regardless of the use of unweighted or weighted algorithms (P < 0.01) (Supplemental Figure 5). In the prefrail group, B. adolescentis was predominant in the prebiotic mixture group, and Faecalibacterium was predominant in the placebo group. In the PIA group, Bifidobacterium pseudocatenulatum and E. coli, Veillonellaceae, Enterobacteriales, and Negativicutes were the dominant bacteria (Supplemental Figure 6). There were 13 and 177 different metabolites between PMA and PIA and between FMA and FIA, respectively (P < 0.05) (Supplemental Figure 7). Compared with those in the FIA group, the overall expression of genes related to protein digestion and absorption, carbon metabolism in cancer centers, mineral absorption, aminoacyl tRNA biosynthesis, ABC transport, and amino acid biosynthesis in the FMA group tended to be downregulated (P < 0.05). A hierarchical clustering heatmap and network map showed that there were 25 different bacterial flora and 36 different metabolites between the PIA and PMA groups, as shown in Supplemental Figure 8, and the network diagram showed that Dialister was the key bacterial group in the core position and was markedly positively correlated with l-methionine, indole, l-alanine, l-tryptophan, phenyllactic acid, sorbitol and indole-3-lactic acid.

Correlation analysis between intestinal flora and clinical indicators (randomized, controlled trial)

To further explore the correlation between the intestinal flora and clinical indicators, we screened the 30 most abundant operational taxonomic units (OTUs) and the expression data of the intestinal flora in the kingdom, phylum, class, order, family, genus, and species. The Pearson correlation algorithm was used to calculate the correlation between species and clinical indicators, and a heatmap was drawn. At the genus level, Bifidobacterium was positively correlated with grip strength, muscle mass, visceral fat, and albumin levels and negatively correlated with exhaustion and frailty scores. The abundance of Blautia in the family Lachnospirillaceae was positively correlated with grip strength and physical activity and negatively correlated with exhaustion and frailty scores and IL-17 levels. Prevotella was positively correlated with slow walking, exhaustion, and frailty scores, as well as with body water percentage, among others, and negatively correlated with grip strength, body fat percentage, and albumin levels, among others (Figure 1A). On the basis of the results of the aforementioned association analysis, we constructed a correlation network map. By examining the degree of connectivity depicted in the figure, we could discern core microorganisms and indicators. The findings revealed positive correlations between muscle mass and Bifidobacterium, Ruminococcus, and Eubacterium halobium. Grip strength was found to have positive associations with Bifidobacterium, Peptostreptococcus, Ruminococcus, and Dorsiella. IGF-1 was positively correlated with Ruminococcus, while albumin was negatively correlated with Prevotella and Klebsiella (Figure 1B). After intervention in the prefrail group, exhaustion was negatively correlated with Ruminococcus and positively correlated with Enterococcus. Weight loss was negatively correlated with Veillonella, and a slow walk was positively correlated with Roseburia, among others (Figure 1C). After intervention in the frail group, the PSQI was positively correlated with Holdemanella, whereas visceral fat, body fat percentage, and IFN-γ levels were positively correlated with Fusobacterium (Figure 1D).

Correlation analysis between metabolites and clinical indicators (randomized, controlled trial)

Likewise, we screened the expression data of the top 30 most abundant metabolites and used the Pearson correlation algorithm to calculate the correlations between the metabolites and clinical indicators. The results showed that a slow walking speed was positively correlated with trans-vaccenic acid, the frailty score was negatively correlated with hydroxyisocaproic acid, and the PAC-QOL score was positively correlated with l-arginine (Figure 2A). The blood urea (BU) levels, cystatin C levels, and body moisture rate were positively correlated with l-pyroglutamic acid; body fat percentage, and visceral fat were negatively correlated with DL-methionine sulfoxide; and grip strength was negatively correlated with l-histidine among prefrail older individuals (Figure 2B). After intervention in the frail group, the core improvement in walking speed (walking time) was mainly positively correlated with metformin, 1-palmitoyl-sn-glycero-3-phosphocholine, and 1-oleoyl-sn-glycero-3-phosphocholine and was negatively correlated with l-methionine and ketoisocaproic acid (Figure 2C).

Discussion

The intestinal microbiota — one of the most densely populated microbial communities on earth — contain highly diverse microbial communities that provide metabolic, immunologic, and protective functions that play a crucial role in human health. Increasingly, the consumption of prebiotics is recognized as an important avenue for modulating the composition and function of the intestinal microbiota (31). In this community-dwelling older adult–based clinical trial, we report an association between the intestinal microbiota and frailty status and further report that supplementation with prebiotics for 12 weeks resulted in a greater improvement in frailty status in older individuals than did placebo. The main mechanisms by which prebiotics may improve frailty status include modulation of the intestinal microbiota and metabolites.

We observed that advanced age, number of offspring, comorbidities, and history of surgery were negatively correlated with frailty severity and that exercise frequency was a protective factor. The intestinal microbiota of adults are dominated by Firmicutes and Bacteroidetes and smaller proportions of Proteobacteria, Actinobacteria, and Verrucomicrobia (32, 33). Previous studies have reported the enrichment of Bacteroidetes and Protobacteria and a decrease in Firmicutes and Bifidobacteria in older people. Rashidah et al. performed a systematic review in 2022 and showed that frail older individuals had lower intestinal microbiota diversity and a decreased abundance of Firmicutes, with Dialister, Lactobacillus, and Ruminococcus being the prominent genera, which is in accordance with our results (34, 35). We found that with increasing frailty severity, the relative abundance of Firmicutes decreased gradually, while that of Bacteroidetes increased. Via the capacity to generate either harmful or beneficial microbial metabolites, including short-chain fatty acids (SCFAs), cholate, and trimethylamine N-oxide (TMAO), as well as protein fermentation products, the intestinal microbiota have been linked to several diseases, such as inflammatory and cardiovascular diseases and metabolic disorders (33, 36–38). A general decrease in total energy, mass, and dietary protein intake metabolic pathways was found to be associated with frailty, as dietary protein intake and circulating amino acids are known to be components of muscle protein and are metabolic centers for several biological processes, including inflammation, insulin sensitivity, and redox homeostasis (39, 40). Our data also suggest a role for metabolic alterations as well as metabolic pathways in varying frailty states.

Given the potential plasticity of the intestinal microbiota, interventions involving diet, prebiotics, probiotics, and even fecal microbiota transplantation represent several promising directions. Ghosh et al. conducted a 12-month Mediterranean-style dietary intervention in 1,200 frail and nonfrail European participants from 65 to 79 years of age and found specific microbiome changes to be positively correlated with markers, such as reduced weakness and improved cognition, and negatively correlated with inflammatory markers (C-reactive protein [CRP], IL-17, etc.) (34). In our study, after a 12-week prebiotic intervention, we found that intervention using a prebiotic mixture reduced the exhaustion score and increased body fat and water percentages of older people in the prefrail group. In the frail group, walking speed and grip strength improved, as did symptoms of constipation. This indicates that a prebiotic mixture can improve the muscle strength of patients with frailty and has a certain effect on alleviating frailty status. In addition, no abdominal pain, diarrhea, or other symptoms were reported in the later period for any of the individuals who insisted on taking the prebiotic mixture, which also reflects the safety of the prebiotic mixture and the tolerance of its long-term use.

Our results showed that, in the prefrail group, the abundance of B. adolescentis, Dorea longicatena, Eubacterium hallii, bacterium_LF-3, Lachnospiraceae_bacterium_1_1_57FAA, and Dorea formicigenerans increased after prebiotic intervention. B. adolescentis is a probiotic bacterium that has recognized therapeutic effects on chronic diarrhea and constipation. It can also increase the activity and content of superoxide dismutase (SOD) in blood, reduce the damage of free radicals to human cells, and play an antiaging role (41, 42). The Lachnospiraceae family is known to participate in the breakdown of carbohydrates into SCFAs, which are believed to play a key role in microbiota-gut-brain cross talk and in the maintenance of intestinal barrier function. In addition, a clinical trial of fecal microbiota transplantation for ulcerative colitis in 2017 revealed that remission of symptoms was associated with enrichment of 2 bacteria: Eubacterium hallii and Roseburia inulinivorans. These microorganisms are thought to promote SFCA production and starch breakdown (43). Interestingly, LefSe analysis showed that in the frail group, prebiotics increased the abundance of the probiotic Bifidobacterium pseudosmall chain; moreover, the abundance of E. coli, a bacterium commonly considered to be an opportunistic pathogen, was also relatively increased. Kong et al. characterized the microbiota of a group of long-lived people (90 years of age or older) in Dujiangyan, China, and revealed that the long-lived group had a greater diversity of gut microbiota than did the young adult group. Further in-depth characterization of the microbiota in the long-lived cohort revealed that several known SCFA-producing bacteria were enriched. However, this result was accompanied by a decrease in some commonly beneficial bacteria (e.g., Faecalis) and an increase in some potentially pathogenic bacteria (e.g., E. coli and Shigella) (44). This finding is consistent with our findings, suggesting that the synergistic or antagonistic effects of the microbiota are complex and that maintaining a diverse and balanced gut microecology may be a key factor in ameliorating frailty (44). We further assessed target metabolism, which showed that prebiotic intervention increased the levels of methionine, histidine, and alanine and that the changes in metabolites tended to be similar to those in nonfrail or nonsarcopenic individuals. Dialister is key within the microbiota and is significantly positively correlated with indole, l-alanine, l-tryptophan and indole-3-lactic acid.

Although our study had several strengths, including a randomized trial design, double-blinded intervention, and rigorous assessment, there were several limitations. There is no clear gold standard for frailty assessment at present; thus, the Chinese version of the Fried Frailty Assessment Method recommended by the Chinese Expert Consensus on Frailty Assessment and Intervention for Elderly Patients was used in our study. It is plausible that the screening method is unsuitable for bedridden older individuals with obvious body dysfunction, and that the use of the bioimpedance analysis for body composition is a less precise measure than CT or MRI. Due to the possible delay between microbiome and metabolome changes, association studies between the metabolome, microbiome, and host state must be performed with caution, and clinical studies aimed at the intervention of metabolites are lacking. Further microbiota studies should include the influence of other phyla (such as viruses, fungi, and archaea), as well as other host characteristics (such as ethnic origin, nutrition, and genetics).

Conclusions.

This clinical trial showed that the diversity, composition, and function of the intestinal microbiome varied with frailty status in community-dwelling older adults in China. Intestinal microbiome dysbiosis is linked to frailty status, and prebiotic mixture interventions may be a promising direction for treatment. Future studies are needed to determine whether other microorganisms participate in the frailty process and which combined therapy with prebiotics may further improve outcomes.

Methods

Sex as a biological variable.

Our research included both men and women.

Design.

We conducted a large multicenter, double-blind, randomized, placebo-controlled trial involving community-dwelling older individuals. The study, conducted at 13 communities in Xi’an, China, was mainly divided into 3 parts: an observational analysis involving 1,693 participants, a cross-sectional analysis with 300 participants, and a randomized, controlled trial comprising 200 participants, which was prespecified in the trial protocol (Figure 3).

Participants.

The study was conducted in the 13 communities of Xi’an city, Shaanxi Province, China. Community-dwelling older individuals who were over 65 years of age were recruited and clinically followed between August 11, 2018, and December 30, 2020. All individuals agreed to participate in the survey. The inclusion criteria were as follows: (a) able to get up from a chair and walk at least 6 meters with or without a walking device; (b) had normal cognitive ability, with the ability to read and express themselves (Researchers had brief conversations with the participants, including asking for their name, address, family information, current season, etc. Second, the prospective participant read a paragraph of text from a newspaper aloud. Those who could read it correctly were considered qualified.); and (c) agreed with the research program and were willing to participate in the survey. The exclusion criteria were as follows: (a) blindness, (b) acute infection, (c) cancer or other serious disease (if the cancer had responded well after surgery, no distant metastasis was found, and no chemotherapy, radiotherapy, or special drugs were needed, the individual was not excluded), or (d) dementia, severe cognitive dysfunction, or mental illness, and were unable to live on their own or were unwilling to participate in the survey.

Randomization and interventions.

PASS11 software was used to calculate sample size, with β = 0.2 and α = 0.05. Fifty participants were planned to be recruited in each group (n = 50 participants in the intervention group and n = 50 participants in the placebo group), with a total of 100 participants to be recruited in the prefrail group and 100 to the frail group. Additional exclusion criteria were as follows: acute or chronic inflammatory disease of the intestines in the previous 3 months; use of antibiotics, probiotics, prebiotics, or synbiotics in the past month; use of laxatives or drugs for diarrhea, proton pump inhibitors, or gastric motility drugs for more than 3 days. Randomization was performed using a dynamic allocation method; random numbers were stratified by sex at a 1:1 ratio, and the details of the allocation sequence and the allocation group were concealed from the researchers. Independent study coordinators dispensed either placebo or prebiotics according to a computer-generated, randomized sequence. The computer automatically generated a random number for each of the 100 persons in the group and then ranked the numbers in descending order, with the first 50 individuals taking the intervention mixture (a prebiotic mixture of inulin and oligofructose [50% each] derived from chicory, 15 g/d, taken after breakfast) and the last 50 individuals taking the placebo (maltodextrin, 15 g/d, taken after breakfast). All participants, study coordinators, and researchers were blinded to the intervention arm throughout the entire study.

Outcomes.

The primary outcomes included the results from the frailty scale. The secondary outcomes were the gut microbial composition and metabolite pathways at the beginning and end of the experiment. Information on the participants’ exercise, diet, and other living habits and general conditions was obtained via a questionnaire, and the investigators received unified training before conducting the survey. Body fat percentage, muscle mass, and visceral fat were measured by a body composition analyzer.

Screen of frailty status.

The Fried scale was used to define frailty status (45), which included (a) unintentional weight loss (unintentional weight loss >4.5 kg or 5% of body weight in the past year); (b) exhaustion (evaluated using the Center for Epidemiological Survey, Depression Scale [CES-D]). That is, the score for any 1 of the 2 questions in CES-D was 2–3 points, which could be determined as the score for the item: (a) I feel like I need to work hard in everything I do; (b) I cannot walk forward (0 score: <1 day; 1 point: 1–2 days; 2 points: 3–4 days; 3 points: >4 days); (c) decreased grip strength (determined by sex and BMI, judged on the basis of the average of the 3 grip strength levels of the dominant hand. Men: BMI ≤24.0 kg/m2, weight ≤29 kg; BMI 24.1–28.0 kg/m2, weight ≤30 kg; BMI >28 kg/m2, weight ≤32 kg. Women: BMI ≤23.0 kg/m2, weight ≤17 kg; BMI 23.1–26.0 kg/m2, weight ≤17.3 kg; BMI 26.1–29.0 kg/m2, weight ≤18 kg; BMI >29 kg/m2, weight ≤21 kg); (d) decreased walking speed (time it took to walk 4.57 meters, by sex and height. Men: height ≤173 cm, ≥7 seconds; height >173 cm, ≥6 seconds; women: height ≤159 cm, ≥7 seconds; height >159 cm, ≥6 seconds); and (e) reduced physical activity (assessed according to the Minnesota Leisure Time Physical Activity (MLTA) questionnaire by sex. Men: <383 kcal/week [~2.5 hours of walking]; women: <270 kcal/week [~2 hours of walking]). Specifically, the grip strength was measured by a Jamar Plus+ grip dynamometer, and all of these indicators were assessed by face-to-face surveys. The presence of 1–2 indicators in older individuals was defined as prefrail, and more than 3 indicators was defined as frail.

Sociodemography and general health status, geriatric scale, “bioimpedance analysis” of body composition variables, daily diet survey, hepatic and renal function, and cytokines.

The sociodemographic and general health status of the participants was assessed in person by staff and included name, sex, date of birth, phone number, ethnicity, occupation, education level, marital status, number of children, and frequency of social visits to the older individual by children, relatives, and friends. The frequency of visits was categorized as follows: (a) regular: at least once weekly; (b) occasional: once or twice monthly; (c) infrequent: once or twice annually; (d) seldom: not visited for over a year. Visits falling under the first category were deemed “frequent,” whereas the remaining 3 categories were amalgamated as “other”. Other information collected included per capita monthly income of the family and living situation, which was categorized as follows: (a) living alone; (b) living with spouse; (c) living with children; (d) living with both spouse and children; (e) other situation (participant was asked to specify). These living situations were further divided into 2 groups: (a) living alone and (b) living with others. The remaining categories were as follows: smoking status, alcohol consumption, exercise frequency, personality type, surgical history, medical history, medication status, and occurrence of acute events.

The common scales for older persons used in this study included the Activities of Daily Living (ADL) (46), the Self-rating Anxiety Scale (SAS) (47), the Geriatric Depression Scale (GDS) (48), Patient Assessment of Constipation–Quality of Life (PAC-QOL) scale (49), and the Pittsburgh Sleep Quality Index (PSQI) (50). The above scales are all internationally recognized and rated according to the corresponding standards for judgment. The detection by bioimpedance analysis (BIA) of body composition variables was strictly controlled by the staff on the basis of the indications. During detection, the older person was allowed to stand on a body composition analyzer (Tanita BC-545N) according to the instructions. The stabilization of the test reading allowed for the sequential recording of various indices, including weight (kg), BMI (kg/m2), fat percentage, muscle mass (kg), bone mass (kg), visceral fat grade, basal metabolism (kcal), and body moisture percentage.

The daily diet survey was conducted using the “3-Day 24-hour Diet Record Questionnaire,” which recorded all the food eaten on Thursday, Friday, and Saturday for 3 consecutive days and entered on a separate sheet for each day. The researchers explained the recording method to the study participants on site and combined it with the food model to help the participants establish the concept of the specific weight of food, emphasizing that all food eaten at home or outside of meals (including snacks) should be entered in the survey table to avoid omissions. After confirming that the individual was able to accurately understand the form, the form was handed to the person or their caregiver. Finally, the outpatient nutrition guidance software program (version 3.0), developed by Shanghai Zhending Health Technology Co., was used to input and export the data.

Biochemical indicators and cytokines were detected in the participants’ blood samples. Fasting venous blood was drawn from all participants in the morning and centrifuged immediately thereafter. The serum isolated from each sample was divided into 2 parts, with 1 part immediately sent for biochemical function detection to the clinical laboratory at Xijing Hospital, which is affiliated with the Air Force Military Medical University; the other part was used for double-antibody sandwich ELISA (Wuhan Elabscience Biotechnology) to detect cytokines.

Determination of fecal microbiota.

Fecal samples were collected at baseline and at the end of the 3-month intervention. The detailed fecal collection process and matters needing attention were formulated, and the researchers and participants were trained at the beginning of the experiment. Each fecal sample (approximately 2 g) was collected by participants at home in a dry, aseptic exclusive stool collector, immediately stored at –20°C, and sent within 1 hour through the cold chain (–80°C) until analysis. DNA was extracted from fecal samples using the SDS method and detected by 16S rDNA gene sequencing. PICRUSt software was used to analyze the function of the gut microbiota. High-throughput chromatography‒mass spectrometry was used to assess the metabolomics of the targeted microbiota.

Statistics.

Descriptive statistics, including the mean, median, and ranges, were used to describe all the quantitative variables. Categorical variables are described by proportions; medians and interquartile distances were used to describe continuous variables that were not normally distributed. ANOVA was used to test the differences between groups of continuous variables, the χ2 test was used to test the differences between groups of categorical variables, and the rank-sum test was used to test non-normally distributed data. Statistical significance was set at a P value of less than 0.05, and statistical analysis was performed using SPSS 25.0 software.

Study approval.

This study conformed to the ethics principles stated in the Declaration of Helsinki, and the project was approved by the Ethics Committee of the First Affiliated Hospital of Air Force Medical University (KY20192015-F-1) and registered in the US Clinical Trial Registry (NCT03995342). All participants were informed of and consented to the study protocol.

Data availability.

The primary data that substantiate the findings presented in this work can be found in the Supporting Data Values file. The data supporting the findings of this study are available from the corresponding author upon reasonable request.

Author contributions

JY and XW conceptualized and designed the study. AW, JY, LH, LS, XJ, RX, and XW acquired and analyzed the data. JY and LH wrote the manuscript. AW, JY, LH, LS, XJ, RX, and XW critically revised the manuscript and approved the final version of the manuscript. XW agreed to be accountable for all aspects of the work and ensured that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.

Supplementary Material

Supplemental data

ICMJE disclosure forms

Supporting data values

This work was supported by the National Key R&D Program of China (project 2020YFC2008000); the Special Project of Military Health Care (19BJZ05), the Key R&D Project of Shaanxi Province (2020SF-225); and the Xijing Hospital discipline boost program (XJZT19PTK16). We wish to thank all of participants for their efforts. We also thank the Fengning Pingan High-Tech Industrial Co. for providing the prebiotics free of charge, as well as Shang Lei and Anhui Wang at the Air Force Medical University for their guidance.

Version 1 09/17/2024

Electronic publication

Version 2 09/18/2024

Typographical error corrected in affiliations list.

Figure 1 Correlation between the flora and clinical indicators.

(A) Correlation between the most abundant flora (top 30) and clinical indicators. (B) Correlation network map between the flora (top 30) and clinical indicators. This network diagram is based on Pearson correlation analysis to calculate the correlation between clinical indicators and intestinal flora and is drawn with a P value of less than 0.5. The red circle represents the microorganism, the blue box represents the clinical index, and the size of nodes represents the size of the surrounding connectivity. The more connections, the larger the size. The solid line represents positive correlation, whereas the dashed line represents negative. (C) Correlation between the flora and clinical indicators among prefrail older individuals (PIA vs. PMA). (D) Correlation between the flora and clinical indicators among frail older individuals (FIA vs. FMA).

Figure 2 Correlation between the metabolites and clinical indicators.

(A) Correlation between the most abundant metabolites (top 30) and clinical indicators. (B) Correlation between the metabolites and clinical indicators among prefrail older individuals (PIA vs. PMA). (C) Correlation between the metabolites and clinical indicators among frail older individuals (FIA vs. FMA).

Figure 3 Trial profile.

Table 8 The microbiota and metabolism after interventions

Table 7 Effect of prebiotics on biochemical indicators and cytokines in prefrail and frail older individuals

Table 6 Effect of prebiotics on general status of prefrailty and frailty elderly

Table 5 The microbiota and metabolism of the 3 groups

Table 4 Liver and renal function and cytokines among groups with different frailty states

Table 3 Frailty indicators, scale scores, and body composition among groups with different frailty states

Table 1 Basic information and frailty status of the screened population

Table 2 Baseline characteristics of participants (n, %)

Conflict of interest: The authors have declared that no conflict of interest exists.

Copyright: © 2024, Yang et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: J Clin Invest. 2024;134(18):e176507.https://doi.org/10.1172/JCI176507.
==== Refs
1 Partridge L et al Facing up to the global challenges of ageing Nature 2018 561 7721 45 56 10.1038/s41586-018-0457-8 30185958
2 World Health Organization. World Health Stastics. https://www.who.int/data/gho/publications/world-health-statistics Updated May 21, 2024. Accessed August 7, 2024
3 Ofori-Asenso R et al Global incidence of frailty and prefrailty among community-dwelling older adults: a systematic review and meta-analysis JAMA Netw Open 2019 2 8 e198398 10.1001/jamanetworkopen.2019.8398 31373653
4 Bernabei R et al Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project) BMJ 2022 377 e068788 10.1136/bmj-2021-068788 35545258
5 Dent E et al Management of frailty: opportunities, challenges, and future directions Lancet 2019 394 10206 1376 1386 10.1016/S0140-6736(19)31785-4 31609229
6 Clegg A et al Frailty in elderly people Lancet 2013 381 9868 752 762 10.1016/S0140-6736(12)62167-9 23395245
7 Damluji AA et al Frailty and cardiovascular outcomes in the National Health and Aging Trends Study Eur Heart J 2021 42 37 3856 3865 10.1093/eurheartj/ehab468 34324648
8 Human Microbiome Project C Structure, function and diversity of the healthy human microbiome Nature 2012 486 7402 207 214 10.1038/nature11234 22699609
9 Milani C et al The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota Microbiol Mol Biol Rev 2017 81 4 e00036 10.1128/MMBR.00036-17 29118049
10 Eckburg PB et al Diversity of the human intestinal microbial flora Science 2005 308 5728 1635 1638 10.1126/science.1110591 15831718
11 Yatsunenko T et al Human gut microbiome viewed across age and geography Nature 2012 486 7402 222 227 10.1038/nature11053 22699611
12 Langille MG et al Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences Nat Biotechnol 2013 31 9 814 821 10.1038/nbt.2676 23975157
13 Hooper LV et al Interactions between the microbiota and the immune system Science 2012 336 6086 1268 1273 10.1126/science.1223490 22674334
14 Lim MY et al Association between gut microbiome and frailty in the older adult population in Korea J Gerontol A Biol Sci Med Sci 2021 76 8 1362 1368 10.1093/gerona/glaa319 33437992
15 Kim YK Shin C The Microbiota-gut-brain axis in neuropsychiatric disorders: pathophysiological mechanisms and novel treatments Curr Neuropharmacol 2018 16 5 559 573 10.2174/1570159X15666170915141036 28925886
16 Lee J et al Gut microbiota-derived short-chain fatty acids promote poststroke recovery in aged mice Circ Res 2020 127 4 453 465 10.1161/CIRCRESAHA.119.316448 32354259
17 Hill C et al Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic Nat Rev Gastroenterol Hepatol 2014 11 8 506 514 10.1038/nrgastro.2014.66 24912386
18 O’Toole P Jeffery I Gut microbiota and aging Science 2015 350 6265 1214 1215 10.1126/science.aac8469 26785481
19 Martina C et al Gut microbiota and physical frailty through the mediation of sarcopenia Exp Gerontol 2019 124 110639 31226349
20 Ticinesi A et al Gut microbiota, muscle mass and function in aging: a focus on physical frailty and sarcopenia Nutrients 2019 11 7 1633 1654 10.3390/nu11071633 31319564
21 Andrea Ticinesi FL et al Can a carnivore diet provide all essential nutrients? Curr Opin Endocrinol Diabetes Obes 2017 27 5 312 1316 32833688
22 Wang X Min W Research progress of gut microbiota and frailty syndrome Open Med (Wars) 2021 16 1 1525 1536 10.1515/med-2021-0364 34712824
23 D’Amico Federicaa BM et al Gut microbiota in relation to frailty and clinical outcomes Curr Opin Clin Nutr Metab Care 2023 26 3 219 225 10.1097/MCO.0000000000000926 36942920
24 Buigues C et al Effect of a prebiotic formulation on frailty syndrome: a randomized, double-blind clinical trial Int J Mol Sci 2016 17 6 932 10.3390/ijms17060932 27314331
25 Theou O et al Can a prebiotic formulation reduce frailty levels in older people? J Frailty Aging 2019 8 1 48 52 30734832
26 Chenhuichen C et al Impact of probiotics and prebiotics in the modulation of the major events of the aging process: A systematic review of randomized controlled trials Exp Gerontol 2022 164 111809 10.1016/j.exger.2022.111809 35469958
27 Jayanamaa K Theou O Effects of probiotics and prebiotics on frailty and ageing: a narrative review Curr Clin Pharmacol 2020 15 3 183 192 10.2174/1574884714666191120124548 31750806
28 Sánchez Y Sánchez de la Barquera B et al Emerging evidence on the use of probiotics and prebiotics to improve the gut microbiota of older adults with frailty syndrome: a narrative review J Nutr Health Aging 2022 26 10 926 935 10.1007/s12603-022-1842-4 36259581
29 Coutts L et al Can probiotics, prebiotics and synbiotics improve functional outcomes for older people: a systematic review Eur Geriatr Med 2020 11 975 993 10.1007/s41999-020-00396-x 32974888
30 Veronese N et al Prevalence of multidimensional frailty and pre-frailty in older people in different settings: A systematic review and meta-analysis Ageing Res Rev 2021 72 101498 10.1016/j.arr.2021.101498 34700009
31 Holscher HD Dietary fiber and prebiotics and the gastrointestinal microbiota Gut Microbes 2017 8 2 172 184 10.1080/19490976.2017.1290756 28165863
32 Du Y et al Effects of anti-aging interventions on intestinal microbiota Gut Microbes 2021 13 1 1994835 10.1080/19490976.2021.1994835 34743658
33 Kåhrström CT et al Intestinal microbiota in health and disease Nature 2016 535 7610 47 10.1038/535047a 27383978
34 Ghosh TS et al Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries Gut 2020 69 7 1218 1228 10.1136/gutjnl-2019-319654 32066625
35 Rashidah NH et al Differential gut microbiota and intestinal permeability between frail and healthy older adults: A systematic review Ageing Res Rev 2022 82 101744 10.1016/j.arr.2022.101744 36202312
36 Koh A et al From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites Cell 2016 165 6 1332 1345 10.1016/j.cell.2016.05.041 27259147
37 Wang Z et al Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease Nature 2011 472 7341 57 63 10.1038/nature09922 21475195
38 Smith PM et al The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis Science 2013 341 6145 569 573 10.1126/science.1241165 23828891
39 Giron M et al Gut microbes and muscle function: can probiotics make our muscles stronger? J Cachexia Sarcopenia Muscle 2022 13 3 1460 1476 10.1002/jcsm.12964 35278043
40 Claesson MJ et al Gut microbiota composition correlates with diet and health in the elderly Nature 2012 488 7410 178 184 10.1038/nature11319 22797518
41 Mondot S et al Structural robustness of the gut mucosal microbiota is associated with Crohn’s disease remission after surgery Gut 2016 65 6 954 962 10.1136/gutjnl-2015-309184 26628508
42 Human Microbiome Project C A framework for human microbiome research Nature 2012 486 7402 215 221 10.1038/nature11209 22699610
43 Paramsothy S et al Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis Gastroenterology 2019 156 5 1440 1454 10.1053/j.gastro.2018.12.001 30529583
44 Kong F et al Gut microbiota signatures of longevity Curr Biol 2016 26 18 R832 R833 10.1016/j.cub.2016.08.015 27676296
45 Fried LP et al Frailty in older adults: evidence for a phenotype J Gerontol A Biol Sci Med Sci 2001 56 3 M146 M156 10.1093/gerona/56.3.M146 11253156
46 Lawton MP Brody EM Assessment of older people: self-maintaining and instrumental activities of daily living Gerontologist 1969 9 3 179 186 10.1093/geront/9.3_Part_1.179 5349366
47 Zung WW A rating instrument for anxiety disorders Psychosomatics 1971 12 6 371 379 10.1016/S0033-3182(71)71479-0 5172928
48 Yesavage JA et al Development and validation of a geriatric depression screening scale: a preliminary report J Psychiatr Res 1982 17 1 37 49 10.1016/0022-3956(82)90033-4 7183759
49 Marquis P et al Development and validation of the patient assessment of constipation quality of life questionnaire Scand J Gastroenterol 2005 40 5 540 551 10.1080/00365520510012208 16036506
50 Buysse DJ et al Patterns of sleep episodes in young and elderly adults during a 36-hour constant routine Sleep 1993 16 7 632 637 8290856
